Document is current
Any future updates will be listed below
-
Authors
Gallon, Richard
Herrero-Belmonte, Patricia
Phelps, Rachel
Hayes, Christine
Sollars, Elizabeth
Egan, Daniel
Spiewak, Helena
Nalty, Sam
Mills, Sarah
Loo, Peh Sun
Borthwick, Gillian M.
Santibanez-Koref, Mauro
Burn, John
McAnulty, Ciaron
Jackson, Michael S.
-
Funding
Funding for this research was provided by:
Cancer Research UK (C569/A24991, C569/A24991, C569/A24991)
NHS England Small Business Research Initiative (SBRIC01P3040, SBRIC01P3040, SBRIC01P3040, SBRIC01P3040, SBRIC01P3040)
The Barbour Foundation (UK charity 328081, UK charity 328081, UK charity 328081)
- License Information
-
More Information
Article History
Received: 29 March 2024
Revised: 31 May 2024
Accepted: 9 June 2024
First Online: 1 July 2024
Competing interests
: R. Gallon, J. Burn, M. S. Jackson, and M. Santibanez-Koref are named inventors on patents covering the microsatellite instability markers analysed: WO/2018/037231 (published March 1, 2018), WO/2021/019197 (published February 4, 2021), and GB2114136.1 (filed October 1, 2021). The other authors declare no conflicts of interest.
: Ethical approval for use of excess diagnostic samples during assay development was granted by the NHS Health Research Authority (REC reference 13/LO/1514). Patient consent was obtained for use of excess diagnostic samples for clinical validation of novel assays. Clinical audits were conducted following The Caldicott Principles ().
